info@marketfacts.ca +1-807 788 8478
ACADIA Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative treatments for neurological, psychiatric, and rare disease conditions.
Anavex is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and neurodevelopmental disorders, using its proprietary SIGMACEPTOR™ platform to target sigma-1 receptor pathways.
Harmony Biosciences Holding, Inc. a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company headquartered in Warminster, Pennsylvania, focused on developing innovative therapies to treat chronic hepatitis B virus (HBV) infection. The company aims to achieve a functional cure for HBV by targeting multiple stages of the virus lifecycle through a combination of RNA interference (RNAi) therapies, capsid inhibitors, immune modulators, and HBV RNA destabilizers. Its lead product candidates include AB-729, an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg), and AB-836, a capsid inhibitor. Leveraging proprietary lipid nanoparticle (LNP) technology for RNA-based therapies, Arbutus is also engaged in collaborations to advance its pipeline. Arbutus is strategically positioned in the biopharmaceutical landscape, aiming to address unmet medical needs in HBV treatment. By pursuing a comprehensive approach that integrates cutting-edge science and collaboration, Arbutus continues to advance its pipeline and work toward transformative solutions for HBV patients globally.
Nautilus Biotechnology Inc. (NASDAQ: NAUT) is a pioneering life sciences company focused on revolutionizing proteomics, the study of proteins and their functions, by developing a next-generation platform for single-molecule protein analysis. Founded in 2016 by Sujal Patel and Parag Mallick, Nautilus aims to address the limitations of current proteomic methods by enabling more comprehensive, sensitive, and scalable analysis of the human proteome.